表紙
市場調查報告書
商品編碼
971910

全球抗癌藥市場規模調查:各藥物類型,各治療類型,各癌症類型,及各地區預測(2020∼2027年)

Global Anticancer Drugs Market Size study, By Drug Type - Cytotoxic Drugs, Targeted Drugs, and Hormonal Drugs), By Therapy Type, By Cancer Type, and Regional Forecasts 2020-2027

出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球抗癌藥的市場規模在2019年估算為約1,054億美金。該市場在2020年∼2027年的預測期間內,預計將以超越6.7%的健全成長率成長。

隨著各國政府和中央政府在全球範圍內開展了許多提高認識的運動,抗癌藥物的銷售勢頭越來越大。美國國家乳腺癌基金會(National Breast Cancer Foundation,Inc.)正在進行一項年度計劃,以宣傳有關該疾病的信息,方法是將10月作為乳腺癌宣傳月,並鼓勵婦女接受篩查。這樣的程序增加了診斷的數量,並且在不知不覺中創建了大量的抗癌藥物患者庫。

本報告提供全球抗癌藥市場相關調查,提供市場概要,以及各藥物類型,各治療類型,各癌症類型用途,及各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 摘要整理

第2章 全球抗癌藥市場定義和範圍

  • 調查的目的
  • 市場定義和範圍
    • 調查範圍
    • 產業的演進
  • 調查對象年度
  • 匯率

第3章 全球抗癌藥市場動態

  • 抗癌藥市場影響分析(2018-2027年)

第4章 全球抗癌藥市場:產業分析

  • 波特的五力分析
  • PEST分析
  • 投資採用模式
  • 分析師的推薦事項與結論

第5章 全球抗癌藥市場,各藥物類型

  • 市場概述
  • 全球抗癌藥市場,效能-潛在性分析:各藥物類型
  • 全球抗癌藥市場預算與預測:2017年∼2027年(10億美元):各藥物類型
  • 抗癌藥市場,子區隔分析
    • 細胞毒性藥
    • 標靶藥物
    • 荷爾蒙劑

第6章 全球抗癌藥市場,各治療類型

  • 市場概述
  • 全球抗癌藥市場,效能-潛在性分析:各治療類型
  • 全球抗癌藥市場預算與預測:2017年∼2027年(10億美元):各治療類型
  • 抗癌藥市場,輔助全球抗癌藥市場,效能-潛在性分析:gumento分析
    • 化療
    • 標靶治療
    • 免疫療法
    • 其他

第7章 全球抗癌藥市場,各癌症類型

  • 市場概述
  • 癌症的種類,各效能的全球抗癌藥市場-潛在性分析:各癌症類型
  • 全球抗癌藥市場預算與預測:2017年∼2027年(10億美元):各癌症類型
    • 肺癌
    • 乳癌
    • 白血病
    • 大腸癌
    • 其他

第8章 全球抗癌藥市場,各地區分析

  • 地區市場概述
  • 北美
    • 美國
    • 加拿大
  • 歐洲的概述
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他
  • 亞太地區的概述
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • 其他
  • 南美的概述
    • 巴西
    • 墨西哥
  • 其他

第9章 競爭資訊

  • 首位市場策略
  • 企業簡介
    • F. Hoffmann-La Roche Ltd
    • Eli Lilly and Company
    • Novartis AG
    • Pfizer Inc
    • Bayer AG
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Merck & Co., Inc.
    • CELGENE CORPORATION
    • Amgen Inc

第10章 調查流程

目錄

Title:
Global Anticancer Drugs Market Size study, By Drug Type - Cytotoxic Drugs (Alkylating Agents, and Antimetabolites), Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors), and Hormonal Drugs), By Therapy Type (Chemotherapy, Targeted Therapy, and Immunotherapy), By Cancer Type (Lung Cancer, Breast Cancer, Leukemia, and Colorectal Cancer), and Regional Forecasts 2020-2027.

Global Anticancer Drugs Market is valued approximately at USD 105.4 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 6.7% over the forecast period 2020-2027. Sales of anti-cancer drugs are gaining momentum, as many awareness campaigns are being undertaken at global level by governments and central authorities. The National Breast Cancer Foundation, Inc. is undertaking an annual initiative to promote information on the disease by observing October as a month of recognition of breast cancer and encouraging women to undergo screening tests. Such programs are rising the number of diagnostics, unwittingly creating a large patient pool for anticancer drugs. The increase in funding to promote research and development of anticancer therapy is contributing to improvements in treatment methods and routes of administration. The creation of therapies with improved patient outcomes and less side-effects than traditional drugs is expected to increase patient confidence in these drugs and thus improve the growth potential of the market for anticancer drugs. Besides, the U.S. The Food and Drug Administration (FDA) determines the status of 'orphan drugs' for drugs that have a promising potential for the treatment of rare diseases. In order to further encourage the production of highly successful medicines for rare diseases such as cancer, the FDA provides benefits such as market exclusivity and tax credits for clinical trials. In the background of these dynamics, the demand for and availability of these drugs is expected to increase, thereby boosting the growth of the global market for anticancer drugs. Anti-cancer drug market sales are projected to rise by 50% over the next five years, primarily due to favorable regulatory scenarios in the U.S. According to the American Cancer Society, the number of deaths worldwide was 8.2 billion in 2012 and is projected to rise over the predicted period. Despite a dramatic increase in cancer diagnosis rates, the sales of anticancer drugs have yet to recognize their true potential. Growing understanding of the side-effects of anticancer treatment, such as hair loss, anemia, constipation, infection and neutropenia, sexual health problems, and bleeding and bruising, is expected to raise the consumer's inclination towards natural therapy. In regions such as Southeast Asia , the Middle East and Africa, India and China, patients are taking alternative therapeutic drugs such as Ayurveda, homoeopathic and herbal medicines, which could have a negative effect on the demand for anticancer drugs during the forecast period (2020-2027).

The regional analysis of global Anticancer Drugs Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is projected to grow at a rapid pace during the forecast period other than Japan and Australia, which appears to be favorable to business growth. Growing recognition of the advantages of early detection, growing disposable incomes, increasing prevalence of the number of types of cancer, and estimated pipeline drugs are driving the growth of the regional sector. Due to the easy availability of drugs in the region and high spending on healthcare from both the private and public sectors, North America is projected to make a major contribution to the global market for anti-cancer drugs. Apart from that, existing players are joining China and India because of the high prevalence of the market making it attractive. Markets in other regions, such as Africa , the Middle East and Latin America, are expected to expand at a moderate pace during the forecast period.

Major market player included in this report are:

  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc
  • Bayer AG
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • Merck & Co., Inc.
  • CELGENE CORPORATION
  • Amgen Inc

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Type:

  • Cytotoxic Drugs
  • Targeted Drugs
  • Hormonal Drugs

By Therapy Type:

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others

By Cancer Type:

  • Lung Cancer
  • Breast Cancer
  • Leukaemia
  • Colorectal Cancer
  • Others

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • ROE
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
  • Rest of the World

Furthermore, years considered for the study are as follows:

  • Historical year - 2017, 2018
  • Base year - 2019
  • Forecast period - 2020 to 2027

Target Audience of the Global Anticancer Drugs Market in Market Study:

  • Key Consulting Companies & Advisors
  • Large, medium-sized, and small enterprises
  • Venture capitalists
  • Value-Added Resellers (VARs)
  • Third-party knowledge providers
  • Investment bankers
  • Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
    • 1.2.1. Anticancer Drugs Market, by Region, 2018-2027 (USD Billion)
    • 1.2.2. Anticancer Drugs Market, by Drug Type, 2018-2027 (USD Billion)
    • 1.2.3. Anticancer Drugs Market, by Therapy Type, 2018-2027 (USD Billion)
    • 1.2.4. Anticancer Drugs Market, by Cancer Type, 2018-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Anticancer Drugs Market Definition & Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Anticancer Drugs Market Dynamics

  • 3.1. Anticancer Drugs Market Impact Analysis (2018-2027)
    • 3.1.1. Market Drivers
    • 3.1.2. Market Challenges
    • 3.1.3. Market Opportunities

Chapter 4. Global Anticancer Drugs Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Anticancer Drugs Market, by Drug Type

  • 5.1. Market Snapshot
  • 5.2. Global Anticancer Drugs Market by Drug Type, Performance - Potential Analysis
  • 5.3. Global Anticancer Drugs Market Estimates & Forecasts by Drug Type, 2017-2027 (USD Billion)
  • 5.4. Anticancer Drugs Market, Sub Segment Analysis
    • 5.4.1. Cytotoxic Drugs
    • 5.4.2. Targeted Drugs
    • 5.4.3. Hormonal Drugs

Chapter 6. Global Anticancer Drugs Market, by Therapy Type

  • 6.1. Market Snapshot
  • 6.2. Global Anticancer Drugs Market by Therapy Type, Performance - Potential Analysis
  • 6.3. Global Anticancer Drugs Market Estimates & Forecasts by Therapy Type, 2017-2027 (USD Billion)
  • 6.4. Anticancer Drugs Market, Sub Segment Analysis
    • 6.4.1. Chemotherapy
    • 6.4.2. Targeted Therapy
    • 6.4.3. Immunotherapy
    • 6.4.4. Others

Chapter 7. Global Anticancer Drugs Market, by Cancer Type

  • 7.1. Market Snapshot
  • 7.2. Global Anticancer Drugs Market by Cancer Type, Performance - Potential Analysis
  • 7.3. Global Anticancer Drugs Market Estimates & Forecasts by Cancer Type, 2017-2027 (USD Billion)
    • 7.3.1. Lung Cancer
    • 7.3.2. Breast Cancer
    • 7.3.3. Leukaemia
    • 7.3.4. Colorectal Cancer
    • 7.3.5. Others

Chapter 8. Global Anticancer Drugs Market, Regional Analysis

  • 8.1. Anticancer Drugs Market, Regional Market Snapshot
  • 8.2. North America Anticancer Drugs Market
    • 8.2.1. U.S. Anticancer Drugs Market
      • 8.2.1.1. Drug Type breakdown estimates & forecasts, 2017-2027
      • 8.2.1.2. Therapy Type breakdown estimates & forecasts, 2017-2027
      • 8.2.1.3. Cancer Type breakdown estimates & forecasts, 2017-2027
    • 8.2.2. Canada Anticancer Drugs Market
  • 8.3. Europe Anticancer Drugs Market Snapshot
    • 8.3.1. U.K. Anticancer Drugs Market
    • 8.3.2. Germany Anticancer Drugs Market
    • 8.3.3. France Anticancer Drugs Market
    • 8.3.4. Spain Anticancer Drugs Market
    • 8.3.5. Italy Anticancer Drugs Market
    • 8.3.6. Rest of Europe Anticancer Drugs Market
  • 8.4. Asia-Pacific Anticancer Drugs Market Snapshot
    • 8.4.1. China Anticancer Drugs Market
    • 8.4.2. India Anticancer Drugs Market
    • 8.4.3. Japan Anticancer Drugs Market
    • 8.4.4. Australia Anticancer Drugs Market
    • 8.4.5. South Korea Anticancer Drugs Market
    • 8.4.6. Rest of Asia Pacific Anticancer Drugs Market
  • 8.5. Latin America Anticancer Drugs Market Snapshot
    • 8.5.1. Brazil Anticancer Drugs Market
    • 8.5.2. Mexico Anticancer Drugs Market
  • 8.6. Rest of The World Anticancer Drugs Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. F. Hoffmann-La Roche Ltd
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Industry Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Eli Lilly and Company
    • 9.2.3. Novartis AG
    • 9.2.4. Pfizer Inc
    • 9.2.5. Bayer AG
    • 9.2.6. AstraZeneca
    • 9.2.7. Takeda Pharmaceutical Company Limited
    • 9.2.8. Merck & Co., Inc.
    • 9.2.9. CELGENE CORPORATION
    • 9.2.10. Amgen Inc

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. GLOBAL ANTICANCER DRUGS MARKET, REPORT SCOPE
  • TABLE 2. GLOBAL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY REGION 2017-2027 (USD BILLION)
  • TABLE 3. GLOBAL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY DRUG TYPE 2017-2027 (USD BILLION)
  • TABLE 4. GLOBAL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY THERAPY TYPE 2017-2027 (USD BILLION)
  • TABLE 5. GLOBAL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY CANCER TYPE 2017-2027 (USD BILLION)
  • TABLE 6. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 7. GLOBAL ANTICANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 8. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 9. GLOBAL ANTICANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 10. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 11. GLOBAL ANTICANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 12. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 13. GLOBAL ANTICANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 14. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 15. GLOBAL ANTICANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 16. U.S. ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 17. U.S. ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 18. U.S. ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 19. CANADA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 20. CANADA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 21. CANADA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 22. UK ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 23. UK ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 24. UK ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 25. GERMANY ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 26. GERMANY ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 27. GERMANY ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 28. ROE ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 29. ROE ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 30. ROE ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 31. CHINA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 32. CHINA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 33. CHINA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 34. INDIA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 35. INDIA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 36. INDIA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 37. JAPAN ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 38. JAPAN ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 39. JAPAN ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 40. ROAPAC ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 41. ROAPAC ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 42. ROAPAC ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 43. BRAZIL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 44. BRAZIL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 45. BRAZIL ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 46. MEXICO ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 47. MEXICO ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 48. MEXICO ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 49. ROLA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 50. ROLA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 51. ROLA ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 52. ROW ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 53. ROW ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 54. ROW ANTICANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 55. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL ANTICANCER DRUGS MARKET
  • TABLE 56. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL ANTICANCER DRUGS MARKET
  • TABLE 57. YEARS CONSIDERED FOR THE STUDY
  • TABLE 58. EXCHANGE RATES CONSIDERED

LIST OF FIGURES

  • FIG 1. GLOBAL ANTICANCER DRUGS MARKET, RESEARCH METHODOLOGY
  • FIG 2. GLOBAL ANTICANCER DRUGS MARKET, MARKET ESTIMATION TECHNIQUES
  • FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
  • FIG 4. GLOBAL ANTICANCER DRUGS MARKET, KEY TRENDS 2019
  • FIG 5. GLOBAL ANTICANCER DRUGS MARKET, GROWTH PROSPECTS 2020-2027
  • FIG 6. GLOBAL ANTICANCER DRUGS MARKET, PORTERS 5 FORCE MODEL
  • FIG 7. GLOBAL ANTICANCER DRUGS MARKET, PEST ANALYSIS
  • FIG 8. GLOBAL ANTICANCER DRUGS MARKET, VALUE CHAIN ANALYSIS
  • FIG 9. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 10. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 11. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 12. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 13. GLOBAL ANTICANCER DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 14. GLOBAL ANTICANCER DRUGS MARKET, REGIONAL SNAPSHOT 2017 & 2027
  • FIG 15. NORTH AMERICA ANTICANCER DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 16. EUROPE ANTICANCER DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 17. ASIA PACIFIC ANTICANCER DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 18. LATIN AMERICA ANTICANCER DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 19. GLOBAL ANTICANCER DRUGS MARKET, COMPANY MARKET SHARE ANALYSIS (2019)